TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1321490

Group type: EXPERIMENTAL
Intervention: 1:200,000 epinephrine in a four percent articaine‐HCl solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1:100,000 epinephrine in a four percent articaine‐HCl solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Volunteers injected without subsequent operation (control group)
Number of subjects: 0
Study: 6514177

Group type: EXPERIMENTAL
Intervention: Pirlindole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pirlindole with ethanol (0.4 g 17 vol%/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31618073

Group type: EXPERIMENTAL
Intervention: Hop-stabilization training program (6 weeks, 18 training sessions)
Number of subjects: 28
Study: 29167910

Group type: EXPERIMENTAL
Intervention: Simplified CPR training
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard CPR training
Number of subjects: 85
Study: 26868318

Group type: EXPERIMENTAL
Intervention: Curved laparoscopic instruments (Group-C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Straight laparoscopic instruments (Group-S)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Curved instruments (after swapping) for Group-S
Number of subjects: 20

Group type: COMPARATOR
Intervention: Straight instruments (after swapping) for Group-C
Number of subjects: 20
Study: 24551029

Group type: EXPERIMENTAL
Intervention: Prophylactic low dose penicillin V (6 months for first episode, 12 months for recurrent cellulitis)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Prophylactic low dose penicillin V
Number of subjects: 397
Study: 21760585

Group type: EXPERIMENTAL
Intervention: Carotenoid supplementation (lutein, lycopene, β‐carotene)
Number of subjects: 203
Study: 20118492

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg once daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard therapy (PEG-IFN-alpha 2b and ribavirin)
Number of subjects: 44
Study: 18057337

Group type: EXPERIMENTAL
Intervention: Walking for 2 hours on Oxford Street
Number of subjects: 60

Group type: COMPARATOR
Intervention: Walking for 2 hours in Hyde Park
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Exposure on Oxford Street
Number of subjects: 60
Study: 15642859

Group type: EXPERIMENTAL
Intervention: Prednisone (0.75 mg/kg daily for the first 10 days of each month for 6 months)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (0.75 mg/kg daily for the first 10 days of each month for 6 months)
Number of subjects: 17
Study: 11851640

Group type: EXPERIMENTAL
Intervention: Structured counselling and follow-up (Intervention group, n = 38)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard advice sheet and referral to GP (Control group, n = 38)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: H. pylori eradicated patients
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: H. pylori persistent patients
Number of subjects: 76
Study: 11284774

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study: 9307912

Group type: EXPERIMENTAL
Intervention: Localized 31P MR spectroscopy in transplant kidneys with rejection
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Localized 31P MR spectroscopy in transplant kidneys with tubular necrosis
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: pH measurement in transplant kidneys with rejection
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: pH measurement in transplant kidneys with tubular necrosis
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (patients with no evidence of transplant dysfunction)
Number of subjects: 37
Study: 8384278

Group type: EXPERIMENTAL
Intervention: 400 mg Lomefloxacin (200 mg b.i.d.)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 600 mg Lomefloxacin (200 mg t.i.d.)
Number of subjects: 122
Study: 3700344

Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Trazodone 100 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29407689

Group type: EXPERIMENTAL
Intervention: Moderate exercise group (MEG; 40-68% of heart rate reserve) for 10min
Number of subjects: 110

Group type: COMPARATOR
Intervention: Passive sitting group (PSG)
Number of subjects: 110
Study: 26707054

Group type: EXPERIMENTAL
Intervention: Annual multimodal screening (MMS)
Number of subjects: 202546

Group type: EXPERIMENTAL
Intervention: Annual transvaginal ultrasound screening (USS)
Number of subjects: 202546

Group type: COMPARATOR
Intervention: No screening (Control)
Number of subjects: 202546

Group type: COMPARATOR
Intervention: MMS vs No screening (excluding prevalent cases)
Number of subjects: 202546
Study: 25193943

Group type: EXPERIMENTAL
Intervention: Painful experiences (ice water immersion, leg squats)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Painful experiences (hot chili pepper)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-pain control treatment
Number of subjects: 0
Study: 23972415

Group type: EXPERIMENTAL
Intervention: Feedback intervention for experimental group patients using the OQ-45 total scale
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (treatment-as-usual)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Feedback intervention for experimental group patients
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Experimental group patients
Number of subjects: 43
Study: 20613472

Group type: EXPERIMENTAL
Intervention: Propofol (2 microg/ml)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 10% Intralipid
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 14
Study: 19024258

Group type: EXPERIMENTAL
Intervention: Brushed machined surfaces
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Brushed plasma sprayed surfaces
Number of subjects: 8

Group type: COMPARATOR
Intervention: Non-brushed machined surfaces
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Machined surfaces
Number of subjects: 8

Group type: COMPARATOR
Intervention: Non-brushed surfaces
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Brushed surfaces
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Implant brushing on machined surfaces
Number of subjects: 8
Study: 16616656

Group type: EXPERIMENTAL
Intervention: dopexamine (2 microg/kg/min, n = 20)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: dopamine (3 microg/kg/min, n = 21)
Number of subjects: 61

Group type: COMPARATOR
Intervention: placebo (n = 20)
Number of subjects: 61
Study: 12647006

Group type: EXPERIMENTAL
Intervention: Intratunical instillation of 2.5 mL of 0.5 % bupivacaine combined with 10 mg/ml methylprednisolone
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group receiving only analgesics postoperatively by intramuscular route
Number of subjects: 65
Study: 11004352

Group type: EXPERIMENTAL
Intervention: Ethyl icosapentate 1800 mg daily and estriol (E3) 2 mg daily (eicosapentaenoic acid group, n = 69)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Estriol (E3) 2 mg daily (control group, n = 72)
Number of subjects: 141
Study: 8976475

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT) combined with trunk strengthening exercises (TSE)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Spinal manipulative therapy (SMT) combined with trunk stretching exercises
Number of subjects: 174

Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drug (NSAID) therapy combined with trunk strengthening exercises (TSE)
Number of subjects: 174
Study: 1361797

Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 54

Group type: COMPARATOR
Intervention: Neomycin sulphate nasal ointment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Neomycin
Number of subjects: 54
Study: 29097103

Group type: EXPERIMENTAL
Intervention: Early introduction of peanut
Number of subjects: 0
Study: 26556234

Group type: EXPERIMENTAL
Intervention: GEM intervention (five 1‐h instructional sessions)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: GEM intervention
Number of subjects: 47
Study: 24253788

Group type: EXPERIMENTAL
Intervention: Actifuse combined with 5 mL of bone marrow aspirate (n = 26)
Number of subjects: 52

Group type: COMPARATOR
Intervention: rhBMP-2 (4.2 mg, n = 26)
Number of subjects: 52
Study: 22089917

Group type: EXPERIMENTAL
Intervention: LISS (Less Invasive Stabilization System)
Number of subjects: 64

Group type: COMPARATOR
Intervention: PFNA (Proximal Femoral Nail Anti-rotation)
Number of subjects: 64
Study: 20823643

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg per day)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Candesartan (8 mg per day)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg per day) in obese subjects
Number of subjects: 85
Study: 18226614

Group type: EXPERIMENTAL
Intervention: Acupuncture (15 sessions over three months)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 201
Study: 15691639

Group type: EXPERIMENTAL
Intervention: HDFU (5FU 3 g/m2 intravenously, 24 h infusion, weekly for 6 weeks)
Number of subjects: 58

Group type: COMPARATOR
Intervention: 5FU+FA+CDDP (5FU 2.0 g/m2 i.v. with folinic acid 500 mg/m2, 2 h-infusion, weekly for 6 weeks + cisplatin 50 mg/m2, once every two weeks for 6 weeks)
Number of subjects: 58
Study: 16285495

Group type: EXPERIMENTAL
Intervention: Patients with perioral dermatitis (PD)
Number of subjects: 40
Study: 10376776

Group type: EXPERIMENTAL
Intervention: Zinc (70 mg, once per week)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Vitamin A (3030 RE, once per week)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Zinc and Vitamin A (70 mg Zn and 3030 RE vitamin A, once per week)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 8687262

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 849

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 849
Study: 1800107

Group type: EXPERIMENTAL
Intervention: Vision condition
Number of subjects: 6

Group type: COMPARATOR
Intervention: No-vision condition
Number of subjects: 6
Study: 6398981

Group type: EXPERIMENTAL
Intervention: Diet rich in PUFA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 30515970

Group type: EXPERIMENTAL
Intervention: adalimumab (TNF inhibitor)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ustekinumab (IL-12/23 inhibitor)
Number of subjects: 50
Study: 30342645

Group type: EXPERIMENTAL
Intervention: Ropivacaine injection (7.5% ropivacaine, 10 mL total, 5 mL each into both uterosacral ligaments)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline injection (10 mL total, 5 mL each into both uterosacral ligaments)
Number of subjects: 40
Study: 26275768

Group type: EXPERIMENTAL
Intervention: Self-managed home-based walking intervention (12 weeks of moderate intensity walking)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 50
Study: 24804802

Group type: EXPERIMENTAL
Intervention: Individually tailored instruction (individual)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Team-tailored instruction (TEAM)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standardized brochures (control)
Number of subjects: 136
Study: 21244523

Group type: EXPERIMENTAL
Intervention: C + 250 FTU
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 32
Study: 20155829

Group type: EXPERIMENTAL
Intervention: SLE patients
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: RA patients
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: MS patients
Number of subjects: 150

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 150
Study: 15988475

Group type: EXPERIMENTAL
Intervention: Patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 12551783

Group type: EXPERIMENTAL
Intervention: Immediate induction of labor (n=124)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Expectant management (n=125)
Number of subjects: 249
Study: 10710805

Group type: EXPERIMENTAL
Intervention: 10% dextrose and 0.075% lidocaine in bacteriostatic water (active solution)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control solution absent 10% dextrose
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 10% dextrose
Number of subjects: 38
Study: 26630718

Group type: EXPERIMENTAL
Intervention: Red Cross Canker Sore Medication
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Maximum Strength Anbesol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Orajel Mouth Aid
Number of subjects: 21
Study: 1490488

Group type: EXPERIMENTAL
Intervention: Droxicam (20 mg single dose)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Droxicam (20 mg/day for 30 consecutive days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Piroxicam (20 mg single dose)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Piroxicam (20 mg/day for 30 consecutive days)
Number of subjects: 25
Study: 3858894

Group type: EXPERIMENTAL
Intervention: 1-mg DST
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 2-mg DST
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Combination of 1-mg and 2-mg DST with 119 semi-consecutive admissions
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 83
Study: 30474431

Group type: EXPERIMENTAL
Intervention: Rocker sole shoes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Flat-bottomed shoes
Number of subjects: 20
Study: 30921979

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (IVLI) 2 mg/minute for 4 hours
Number of subjects: 111

Group type: COMPARATOR
Intervention: Normal saline solution 0.9% (Control)
Number of subjects: 111
Study: 28589771

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 13
Study: 25758436

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) used before, during and after HIFU treatment (Group A)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No CEUS administered (Group B)
Number of subjects: 33
Study: 24061557

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (L-CHO) diet
Number of subjects: 47

Group type: COMPARATOR
Intervention: High-carbohydrate (H-CHO) diet
Number of subjects: 47
Study: 21051458

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Medical treatment (rate control)
Number of subjects: 41
Study: 19337241

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 60
Study: 16455834

Group type: EXPERIMENTAL
Intervention: Vibration
Number of subjects: 18

Group type: COMPARATOR
Intervention: Flutter(R)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Percussion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Acapella(R)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Positive expiratory pressure
Number of subjects: 18
Study: 15190528

Group type: EXPERIMENTAL
Intervention: MCC-135 5 mg, twice daily
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: MCC-135 25 mg, twice daily
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: MCC-135 50 mg, twice daily
Number of subjects: 511

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study: 12587476

Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy only, delivered with megavoltage linear accelerator, combined with intracavitary brachytherapy in some patients, total tumor dose range 55-75 Gy
Number of subjects: 34
Study: 9572815

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (30 g creatine + 30 g dextrose per day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (30 g dextrose per day)
Number of subjects: 8
Study: 8589479

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon-alpha cream (2x10(6) IU/g) applied thrice daily for 5 consecutive days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 60
Study: 2751920

Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 0
Study: 775616

Group type: EXPERIMENTAL
Intervention: Colo-rectal operations
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: All operations
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Operation wounds
Number of subjects: 56
Study: 31291984

Group type: EXPERIMENTAL
Intervention: Pharmacopuncture with hominis placenta extract (PLC), administered twice a week for a total of 18 sessions over 9 weeks.
Number of subjects: 128

Group type: COMPARATOR
Intervention: Injections of normal saline, administered at the same acupoints during the same period as PLC.
Number of subjects: 128
Study: 28506917

Group type: EXPERIMENTAL
Intervention: Atrial antitachycardia pacing plus managed ventricular pacing (DDDRP+MVP)
Number of subjects: 1166

Group type: COMPARATOR
Intervention: Dual-chamber pacing (Control DDDR)
Number of subjects: 1166

Group type: COMPARATOR
Intervention: Managed ventricular pacing (MVP)
Number of subjects: 1166
Study: 25000447

Group type: EXPERIMENTAL
Intervention: Term-SGA
Number of subjects: 4130

Group type: EXPERIMENTAL
Intervention: Preterm-SGA
Number of subjects: 4130

Group type: EXPERIMENTAL
Intervention: Preterm-AGA
Number of subjects: 4130
Study: 23432520

Group type: EXPERIMENTAL
Intervention: Intermediate alcohol consumption
Number of subjects: 41

Group type: COMPARATOR
Intervention: Light alcohol consumption
Number of subjects: 41

Group type: COMPARATOR
Intervention: Heavy alcohol consumption
Number of subjects: 41

Group type: COMPARATOR
Intervention: Negative mood
Number of subjects: 41
Study: 20735800

Group type: EXPERIMENTAL
Intervention: 0-1-12 months vaccination schedule
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: 0-1-6 months vaccination schedule
Number of subjects: 399

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 399
Study: 19221299

Group type: EXPERIMENTAL
Intervention: ACE D/I polymorphism (DD and DI genotypes)
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: ACE D/I polymorphism (II genotype)
Number of subjects: 25000

Group type: COMPARATOR
Intervention: ACE D/I polymorphism
Number of subjects: 25000
Study: 17014060

Group type: EXPERIMENTAL
Intervention: Protease inhibitors (PIs)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-protease inhibitors (non-PIs)
Number of subjects: 21
Study: 15341255

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice a day) + Diane35 (for the first two months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Metformin (850 mg twice a day)
Number of subjects: 30
Study: 11703472

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan
Number of subjects: 273
Study: 9149164

Group type: EXPERIMENTAL
Intervention: Interferon gamma (IFN‐gamma) levels in nasal polyps
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Previous polypectomy surgery
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Subpopulations based on IFN‐gamma levels
Number of subjects: 27
Study: 7967853

Group type: EXPERIMENTAL
Intervention: Self-administered symptom severity scale
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Self-administered functional status scale
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Self-administered activities of daily living scale
Number of subjects: 74

Group type: COMPARATOR
Intervention: Traditional measures of strength and sensibility
Number of subjects: 74
Study: 3410484

Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide (60 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactose (60 mg)
Number of subjects: 0
Study: 31401126

Group type: EXPERIMENTAL
Intervention: Automated Pump System (APS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Gravity Flow System (GFS)
Number of subjects: 42
Study: 29871197

Group type: EXPERIMENTAL
Intervention: Sodium pyruvate nasal spray
Number of subjects: 53
Study: 24317176

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg
Number of subjects: 736

Group type: COMPARATOR
Intervention: Fulvestrant 250 mg
Number of subjects: 736
Study: 22900930

Group type: EXPERIMENTAL
Intervention: General anesthesia plus thoracic epidural anesthesia (GA + TEA)
Number of subjects: 540

Group type: COMPARATOR
Intervention: General anesthesia only (GA)
Number of subjects: 540
Study: 20817638

Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Jazz music
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hip-hop music
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Jamaican music
Number of subjects: 10
Study: 17646506

Group type: EXPERIMENTAL
Intervention: 5 mL saline (distention)
Number of subjects: 203

Group type: COMPARATOR
Intervention: 2 mL (nondistention)
Number of subjects: 203
Study: 16238116

Group type: EXPERIMENTAL
Intervention: Fluvastatin (Lescol) 40 mg once daily at bedtime for 6 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Atorvastatin (Sortis) 10 mg once daily at bedtime for 6 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (clinically healthy subjects)
Number of subjects: 35
Study: 12396958

Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment with amoxicillin, clarithromycin, and omeprazole for 7 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo treatment for 7 days
Number of subjects: 49
Study: 10685268

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40
Study: 7531394

Group type: EXPERIMENTAL
Intervention: G‐CSF 200 micrograms per square meter per day subcutaneously until ANC > 1,500/mm³ (group B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: G‐CSF prophylactically used in high-dose cytosine arabinoside regimens (group C)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No G‐CSF used (group A)
Number of subjects: 50
Study: 2360871

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (60 min per day, 3.5 days per week, targeting 75‐80% of maximum aerobic working capacity)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Organized walking (control group, 60 min per day, 4.1 days per week)
Number of subjects: 78
Study: 6994866

Group type: COMPARATOR
Intervention: Imidazole carboxamide (DTIC) alone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: DTIC plus Corynebacterium parvum
Number of subjects: 49
Study: 31599476

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg or 300 mg
Number of subjects: 3010

Group type: COMPARATOR
Intervention: Etanercept 50 mg (active comparator)
Number of subjects: 3010

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3010